<span data-teams="true">Efficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programs
Orforglipron shows a statistically significant reduction in HbA1c and body weight in type 2 diabetes, but the clinical relevance of these findings should be carefully considered.
Where it sits
this study against the rest of the orforglipron (ly-3502970) corpusSummary and findings
This systematic review assessed the efficacy and safety of orforglipron and danuglipron in adults with type 2 diabetes and/or obesity. A total of 9,693 participants were included from 13 phase 2/3 randomized controlled trials. Orforglipron demonstrated a pooled HbA1c reduction of −1.14 percentage points versus placebo.
Abstract
<h4>Background: </h4> /Objectives: Orforglipron and danuglipron are the two most clinically advanced oral small-molecule (non-peptide) GLP-1 receptor agonists, sharing a common mechanism of action but markedly different regulatory outcomes — approval versus discontinuation. No existing review synthesizes their complete registrational evidence. <h4>Methods:</h4> We systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science (inception to September 2026; PROSPERO-registered protocol) for phase 2/3 randomized controlled trials of orforglipron or danuglipron in adults with type 2 diabetes and/or obesity. Risk of bias was assessed with Cochrane RoB 2. Comparable trials were pooled using random-effects meta-analysis; clinically heterogeneous or non-comparable trials were synthesized narratively. <h4>Results:</h4> Of 505 records identified (286 after deduplication), 13 phase 2/3 randomized controlled trials met the registered eligibility criteria (10 orforglipron, 3 danuglipron); a further 17 reports (phase 1, mechanistic, or post hoc analyses of these trials) were retained only as contextual evidence. Of the 13 eligible trials, 9 (6 orforglipron phase 3, 3 danuglipron phase 2; N=9,693) were included in the quantitative synthesis, of which subsets sharing a common comparator were combined by random-effects meta-analysis (3 trials for HbA1c, 2 for body weight in type 2 diabetes); the remainder are reported as standalone estimates. Orforglipron produced a pooled HbA1c reduction of −1.14 percentage points versus placebo (95% CI −1.25 to −1.02; I²=0%) and superior glycemic control versus dapagliflozin and oral semaglutide. Weight loss varied by population: −9.10% in obesity without diabetes (single trial) and a pooled −6.54% in type 2 diabetes (95% CI −7.96 to −5.11; I²=49.8%, explained by background therapy). No hepatic safety signal was observed across 11,220 pooled orforglipron participants. Danuglipron showed comparable glycemic and weight efficacy but substantially higher, dose-dependent discontinuation (up to 72.7% in one arm), and its development was discontinued after a probable drug-induced liver injury case identified in a later, unpublished study. <h4>Conclusions:</h4> Despite a shared molecular target, orforglipron and danuglipron followed divergent clinical trajectories driven by differences in dosing regimen, tolerability, and hepatic safety rather than by pharmacodynamic efficacy, which was broadly comparable between the two molecules. These findings underscore that efficacy alone is an incomplete predictor of clinical success for oral small-molecule GLP-1 receptor agonists.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.